ArticleOncotarget2018
Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- The prognostic value of indoleamine 2,3-dioxygenase in colorectal cancer: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2021Pooled it
- Evaluation of the Expression of IDO and PTEN in Human Kidney Cancer.Current issues in molecular biology · 2025Article
- Fighting in a wasteland: deleterious metabolites and antitumor immunity.The Journal of clinical investigation · 2022Review
- Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer.Frontiers in immunology · 2022Review
- Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls.Frontiers in medicine · 2021Article
- Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.Frontiers in immunology · 2021Review
- Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors.Journal of immunotherapy and precision oncology · 2020Review
- Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma.Cancers · 2020Review
- Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.Cancer immunology research · 2020Article
- IDO Expression in Cancer: Different Compartment, Different Functionality?Frontiers in immunology · 2020Review
- Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.Frontiers in immunology · 2020Article
- Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.Current oncology reports · 2019Review
- Tryptophan Metabolism as Source of New Prognostic Biomarkers for FAP Patients.International journal of tryptophan research : IJTR · 2019Article
- The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy.Frontiers in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting immune checkpoint molecules has become a major new strategy in the treatment of several cancers. Indoleamine 2,3-dioxygenase (IDO)-inhibitors are a potential next-generation immunotherapy, currently investigated in multiple phase I-III trials. IDO is an intracellular immunosuppressive enzyme and its expression/activity has been associated with worse prognosis in several cancers. The aim of this study was to investigate the expression pattern of IDO in colorectal cancer (CRC). In a cohort of 94 CRC patients, primary tumors (PTs) with corresponding tumor-draining lymph nodes (TDLNs,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.